ESI Group: A More Inclusive and Safer Industry for Women and Everyone Thanks to Simulation
Regulatory News:
ESI Group (Paris:ESI) (ISIN Code: FR0004110310, Symbol: ESI) is a global partner in simulation and virtual prototyping software for various industries. The company is committed to promoting gender equality through various actions, including the recruitment of women and their professional development within the industry. In addition, the Group is advocating for a swift change in legislation to allow the use of virtual prototyping in certification tests in the automotive industry, with the ultimate goal of ensuring the safety of all users, irrespective of their gender or body shape.
According to the World Economic Forum, women are 47% more likely than men to be seriously injured in a car accident. The study of the Insurance Institute of Highway Safety (IIHS) published in 2021 underlines that women have a mortality rate 20 to 28% higher than men during a road accident, a situation explained in part because of the poor consideration of female morphology in crash tests.
Florence Barré, Women@ESI General Delegate and Chief of Staff to Cristel de Rouvray, CEO of ESI Group: " The role of digitization in ensuring highway safety cannot be overstated. By incorporating diverse morphologies in simulations, virtual prototyping can better protect the entire population. Although the automotive industry has widely adopted virtual prototyping, the use of virtual human models that account for a wide range of morphologies remains optional. Therefore, legislators must take an active role in encouraging the systematic adoption of these practices to ensure optimal safety for all users, regardless of their gender or body shape."
Crash tests that no longer correspond to the reality of society
The current system that we have inherited today has remained relatively unchanged for the past 50 years. Mandatory physical tests in the automotive industry no longer reflect the reality of modern society. Shockingly, only one out of the five dummy models used in crash tests until recently was designed to represent female physiology. This particular model, created in the late 1980s, was based on just 5% of the female population and was mostly used in the front and rear passenger positions, with very little consideration for the driver's seat in regulatory test scenarios.
Towards a major breakthrough?
In a significant milestone for both technological advancement and industry awareness, a team of Swedish engineers announced the creation of the world's first female crash test dummy late last year. This achievement highlights the increasing importance of gender inclusion and equality, which are rapidly gaining traction worldwide. However, the question remains: how can we ensure that this breakthrough is accessible and available to all?
The use of digital human models
ESI Group firmly believes that regulatory evolution is necessary to encourage the adoption of agile and inclusive methods, rather than relying solely on physical tests and prototypes as reference tools for passive safety certifications. Moving towards a more virtual and diverse approach enables the representation of current driving practices, including various morphotypes and passenger positions.
Virtual prototyping allows for flexible parameter modifications and facilitates testing on all morphotypes, enabling even more comprehensive results. Additionally, simulation can incorporate morphological diversity in a faster and less expensive manner. Many of ESI Group's industrial partners are already utilizing virtual prototyping to address this challenge. In fact, ESI Group was the first to perform a virtual crash test on the Volkswagen Polo back in 1985, allowing major automotive OEMs to conduct virtual testing of their prototypes instead of costly and time-consuming physical tests.
About ESI Group
Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time, while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval and heavy industry, ESI is present in more than 20 countries, employs 1000 people around the world and reported 2022 sales of €130 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com.
Follow ESI LinkedIn | Facebook | Twitter | YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005777/en/
Contact information
ESI Group
Florence Barré
press@esi-group.com
+33 1 49 78 28 28
Aline Besselièvre
aline.besselievre@gmail.com
+33 6 61 85 10 05
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy7.11.2025 18:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. Data from the study showed that kidney function (eGFR) remained stable in patients with IgA nephropathy through Week 96 – up to 18 months after the last mezagitamab dose.1 The results were presented at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston. IgA nephropathy is a lifelong progressive autoimmune disease often diagnosed in young people aged 10-30 years old that causes irreversible damage to the kidney function.2 It has no cure, and despite available treatments, approximately one in five patients experience renal failure within 10 years of diagnosis.3 By depleting cells that produce an abnormal protein called Gd-IgA1 implicated in the pathogenesis, mezagitamab targets early steps in the process lea
Oremus Corporate Services Expands into Europe with Launch in Finland7.11.2025 17:23:00 EET | Press release
Oremus Corporate Services Private Limited, a multinational Finance and Accounting Advisory firm having its offices in the USA, India and the UK, has announced the extension of its services to Finland, marking the company’s foray into the European market. With over two decades of expertise in accounting, payroll, tax compliance, and advisory services, Oremus has earned trust as a technology-driven finance partner serving clients across geographies. Oremus is an ISAE 3402, ISO 27001, GDPR & DPDP Compliant Company, adhering to International Quality and Security Standards. “Finland isn’t just a new market for us — it’s the gateway to meaningful, growth-driven partnerships across Europe”. said Lalit Ananth Chawla, CEO of Oremus. Having established a strong reputation for delivering reliable Accounting and Advisory solutions to scale-ups and growing businesses, we seek to collaborate with like-minded firms and investors to build a trusted growth ecosystem. Our vision is to offer technology-d
Experian Named a Leader in IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment7.11.2025 16:00:00 EET | Press release
Experian today announced it has been named a leader in the IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment (doc # US52985325, September 2025). The report evaluates vendors on the depth and breadth of their identity verification capabilities and on how effectively they align with current and future customer needs. The IDC MarketScape methodology for this assessment involved two key measures of success: capabilities that reflect Experian’s current menu of services and how well aligned they are to its customer needs as well as strategies that indicate how well Experian’s future strategy aligns with what customers will require in three to five years. “This assessment offers a 360-degree view of our identity-verification solutions, and we’re very proud to be recognized as a leader,” said Keith Little, President of Experian Software Solutions at Experian. “Experian continues to listen to our clients and focus heavily on product development across
Rachelle Alexis Lim is appointed CEO of MultiSafepay as the Company Aims to Better Serve European SMEs with Innovative Solutions7.11.2025 15:12:00 EET | Press release
MultiSafepay, a leading European payment service provider, today announces that Rachelle Alexis Lim has been appointed as the new Chief Executive Officer (CEO) of MultiSafepay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107657130/en/ Rachelle Alexis Lim is appointed CEO of MultiSafepay. In her new role, Lim oversees the overall business strategy and operations of MultiSafepay, leading the company to serve a fast-growing client base of SMEs (small and medium-sized enterprises) in Europe, leveraging innovative solutions to drive their inclusive growth. She now also sits on its board of directors, following approval from the Dutch central bank, De Nederlandsche Bank (DNB). Founder Olaf Geurs, who has served as CEO since establishing MultiSafepay in 1999, will remain Chief Technology Officer (CTO). Geurs will continue to serve on the board of directors, where he and the other existing members will be joined by Lim. In his
Organon Announces Agreement to Divest its JADA ® System for Up to $465 Million to Laborie7.11.2025 14:30:00 EET | Press release
Organon (NYSE: OGN), (“Organon” or “the Company”) a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement with Laborie Medical Technologies Corp. (“Laborie”), a leading diagnostic and therapeutic medical technology company, for them to acquire the JADA System. The transaction, valued at up to $465 million, is comprised of $440 million to be paid at closing, subject to certain closing adjustments, and a potential payment of up to $25 million subject to the achievement of certain 2026 revenue targets. Approximately 100 employees are expected to transfer to Laborie as part of the agreement. “I am incredibly proud of the work the JADA team and Organon have done to help more than 136,000 new mothers in over 20 countries, positioning JADA as a recognized standard of care in postpartum hemorrhage (PPH) management,” said Organon Interim Chief Executive Officer (“CEO”) Joseph Morriss
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom